Načítá se...
Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes
INTRODUCTION: Ticagrelor, the first direct-acting, reversibly binding oral P2Y12 receptor antagonist, appears to have a favorable efficacy and safety profile. AIMS: To update the evidence and provide an overview of the available data on ticagrelor. EVIDENCE REVIEW: Peer reviewed articles published a...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3065559/ https://ncbi.nlm.nih.gov/pubmed/21468241 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CE.S9510 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|